Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
European Journal of Cancer2017Vol. 86, pp. 334–348
Citations Over TimeTop 1% of 2017 papers
Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld, Jean‐Jacques Grob, Brigitte Dréno, Laurent Mortier, Paolo A. Ascierto, Lisa Licitra, Caroline Dutriaux, L. Thomas, Nicolás Meyer, B. Guillot, Reinhard Dummer, Petr Arenberger, Kate Fife, A. Raimundo, Emi Dika, Natalie Dimier, A. Fittipaldo, Ioannis Xynos, Johan Hansson
Abstract
The primary analysis of STEVIE demonstrates that vismodegib is tolerable in typical patients in clinical practice; safety profile is consistent with that in previous reports. Long-term exposure was not associated with worsening severity/frequency of TEAEs. Investigator-assessed response rates showed high rate of tumour control. CLINICALTRIALS.GOV: NCT01367665.
Related Papers
- → Induction Hedgehog pathway inhibition followed by combined‐modality radiotherapy for basal cell carcinoma(2015)29 cited
- → Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma(2015)7 cited
- → The Role of Vismodegib in the Management of Advanced Basal Cell Skin Cancers: A Review(2014)1 cited
- → Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib(2021)1 cited
- The role of the dermatologist in diagnosing, managing advanced basal cell carcinoma(2014)